0001140361-22-018976.txt : 20220513 0001140361-22-018976.hdr.sgml : 20220513 20220513084331 ACCESSION NUMBER: 0001140361-22-018976 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220513 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intersect ENT, Inc. CENTRAL INDEX KEY: 0001271214 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 200280837 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36545 FILM NUMBER: 22920384 BUSINESS ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-641-2100 MAIL ADDRESS: STREET 1: 1555 ADAMS DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: SINEXUS INC DATE OF NAME CHANGE: 20031124 8-K 1 brhc10037433_8k.htm 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
May 13, 2022
Date of Report
(Date of earliest event reported)

Intersect ENT, Inc.
(Exact name of Registrant as Specified in Its Charter)


Delaware
001-36545
20-0280837
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1555 Adams Drive
Menlo Park, California 94025
(Address of principal executive offices, including zip code)

(650) 641-2100
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):


 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.001 par value
  
XENT
  
The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Introductory Note

As previously disclosed in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 10, 2021, Intersect ENT, Inc., a Delaware corporation (the “Company” or “Intersect”), entered into an Agreement and Plan of Merger, dated August 6, 2021 (the “Merger Agreement”), with Medtronic, Inc., a Minnesota corporation (“Parent”), and Project Kraken Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“Merger Sub”).

On May 13, 2022, the Company completed its merger with Merger Sub pursuant to the terms of the Merger Agreement, whereby Merger Sub merged with and into the Company, in accordance with the General Corporation Law of the State of Delaware, with the Company continuing as the surviving corporation (the “Surviving Corporation”) and as a wholly-owned subsidiary of Parent (the “Merger”).

Pursuant to the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each:

(i) share of Company common stock, par value $0.001 per share (“Company Common Stock”) issued and outstanding as of immediately prior to the Effective Time (other than (A) Company Common Stock owned by the Company as treasury stock, (B) Company Common Stock owned by Parent or Merger Sub and (C) Company Common Stock held by a Company stockholder who properly demands appraisal for such dissenting shares) was cancelled and retired, and automatically converted into the right to receive cash in an amount equal to $28.25, without interest (the “Per Share Price”);

(ii) share of Company Series DF-1 Preferred Stock issued and outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash equal to the Per Share Price multiplied by a factor of 1,000;

(iii) stock option granted by the Company to purchase Company Common Stock (each, a “Company Option”), restricted stock unit award (each, a “Company RSU”) and restricted stock unit award with performance-based vesting requirements (each, a “Company PSU”) that was unexpired, unexercised, outstanding and vested as of immediately prior to the Effective Time or that vested solely as a result of the consummation of the transactions contemplated by the Merger Agreement (each, a “Vested Award”) was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of shares subject to such Vested Award, multiplied by (2) the Per Share Price (or, for each Company Option, the excess, if any, of the Per Share Price over such Company Option’s per share exercise price);

(iv) Company Option not subject to performance-based vesting requirements and Company RSU that was unexpired, unexercised, outstanding and unvested as of immediately prior to the Effective Time (each, an “Unvested Non-Performance Award”) was canceled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of shares subject to such Unvested Non-Performance Award, multiplied by (2) the Per Share Price (or, for each Company Option, the excess, if any, of the Per Share Price over such Company Option’s per share exercise price); and

(v) Company Option subject to performance-based vesting requirements and Company PSU that was unexpired, unexercised, and outstanding as of immediately prior to the Effective Time that was not a Vested Award will be automatically cancelled and terminated without payment or distribution being made in respect thereof. For the avoidance of doubt, any Company Options (whether vested or unvested) that had a per share exercise price equal to or greater than the Per Share Price was cancelled immediately upon the Effective Time without payment or consideration.

The foregoing description of the Merger Agreement and the transactions contemplated thereby contained in this Introductory Note does not purport to be complete and is subject to and qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K.

Item 1.02
Termination of a Material Definitive Agreement.

In connection with the consummation of the Merger, on May 13, 2022, Intersect will have repaid all of the outstanding obligations in respect of principal, interest, fees and expenses under (i) the Facility Agreement, dated as of May 11, 2020, by and among Intersect, certain of Intersect’s subsidiaries as guarantors from time to time party thereto, the lenders party thereto and Deerfield Partners, L.P., as agent for itself and the lenders party thereto (the “Existing Convertible Note Facility Agreement”) including payment of the Successor Major Transaction Consideration (as defined in the Existing Convertible Note Facility Agreement), and (ii) the Facility Agreement, dated as of July 22, 2021, by and among Intersect, certain of Intersect’s subsidiaries as guarantors from time to time party thereto, the lenders party thereto and Deerfield Partners, L.P., as agent for itself and the lenders party thereto (the “Existing Term Loan Agreement” and, together with the Existing Convertible Note Facility Agreement, the “Existing Facility Agreements”). The Existing Facility Agreements will have been terminated and all obligations thereunder will have been satisfied effective May 13, 2022. The disclosure under the Introductory Note is incorporated herein by reference.

Item 2.01
Completion of Acquisition or Disposition of Assets.

As described in the Introductory Note, on May 13, 2022, the Merger was completed. Upon the consummation of the Merger, the Company became a wholly-owned subsidiary of Parent. The disclosure under the Introductory Note is incorporated herein by reference.

Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

The disclosures under the Introductory Note are incorporated herein by reference. On May 13, 2022, the Company (i) notified The Nasdaq Global Market (“Nasdaq”) of the consummation of the Merger and (ii) requested that Nasdaq (A) suspend trading of the Company Shares effective before the opening of trading on May 13, 2022 and (B) file with the SEC a Form 25 Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to effect the delisting of the Company Shares from Nasdaq and to deregister the Company Shares under Section 12(b) of the Exchange Act. In addition, the Company intends to file with the SEC a Certification and Notice of Termination of Registration on Form 15 requesting that the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.

Item 3.03
Material Modification to Rights of Security Holders.

The disclosures under the Introductory Note and Items 2.01, 3.01 and 5.03 are incorporated herein by reference.

At the Effective Time, each holder of Company Shares outstanding immediately prior to the Effective Time ceased to have any rights as a stockholder of the Company (other than the right to receive the Per Share Price for such stockholder’s shares of Company Common Stock or the Per Share Price multiplied by a factor of 1,000 for such shareholder’s shares of Company Series DF-1 Preferred Stock), except that those shares that were owned by the Company or owned by Parent or Merger Sub were cancelled.

Item 5.01
Changes in Control of Registrant.

The disclosures under the Introductory Note and Items 2.01, 3.01, 5.02 and 5.03 are incorporated herein by reference.

As a result of the Merger, a change in control of the Company occurred, and the Company became a wholly-owned subsidiary of Parent.

Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The disclosures under the Introductory Note and Item 2.01 are incorporated herein by reference.

Pursuant to the Merger Agreement, effective as of, and contingent upon, the occurrence of the closing of the Merger (the “Closing”), each of Neil A. Hattangadi, Kieran T. Gallahue, Teresa L. Kline, Cynthia L. Lucchese, Dana G. Mead, Jr., Elisabeth Sandoval-Little and Thomas A. West ceased serving as a member of the board of directors of the Company and each committee thereof and each of Thomas A. West, Richard A. Meier, Reyna M. Fernandez and Patrick A. Broderick ceased serving as an officer of the Company.

Further, pursuant to the Merger Agreement, effective as of, and contingent upon, the occurrence of the Closing, (i) the directors of Merger Sub in place as of immediately prior to the Effective Time became the directors of the Surviving Corporation and (ii) the officers of Merger Sub in place as of immediately prior to the Effective Time became the officers of the Surviving Corporation.

Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change of Fiscal Year.

The disclosures under the Introductory Note and Item 2.01 are incorporated herein by reference.

Pursuant to the Merger Agreement, effective as of the Effective Time, the amended and restated certificate of incorporation of the Company and the amended and restated bylaws of the Company were each amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.

Item 8.01
Other Events.

On May 13, 2022, Parent issued a press release announcing the completion of the Merger. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01
Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.
Description
   
Agreement and Plan of Merger, dated as of August 6, 2021, by and among Medtronic, Inc., Project Kraken Merger Sub, Inc. and Intersect ENT, Inc. (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on August 10, 2021)
   
Amended and Restated Certificate of Incorporation of Intersect ENT, Inc.
   
Amended and Restated Bylaws of Intersect ENT, Inc.
   
Press Release, dated as of May 13, 2022
   
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).

*
Schedules omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplemental copies of any omitted schedules to the SEC upon its request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
INTERSECT ENT, INC.
      
 
By:
 /s/ Chris Cleary
    Chris Cleary
Date: May 13, 2022
  
Senior VP, Corporate Development


EX-3.1 2 brhc10037433_ex3-1.htm EXHIBIT 3.1
Exhibit 3.1
 
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
INTERSECT ENT, INC.

1.
The name of the corporation shall be Intersect ENT, Inc. (the “Corporation”).

2.
The address of its registered office in the State of Delaware is: Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at such address is Corporation Service Company.

3.
The nature of the business or purposes to be conducted or promoted by the corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the “DGCL”).
 
4.
The total number of shares of stock which the Corporation shall have authority to issue is 1,000 shares of Common Stock and the par value of each of such shares is $0.01.

5.
The Corporation is to have perpetual existence.

6.
The Board of Directors shall have the power to adopt, amend or repeal the by-laws.

7.
Elections of directors need not be by written ballot unless the by-laws of the Corporation shall so provide.

8.
Meetings of stockholders may be held within or without of the State of Delaware, as the by-laws may provide. The books of the Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the board of directors or in the by-laws of the Corporation.
 
9.
The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders herein are granted subject to this reservation.

10.
Section 203 of the DGCL shall not apply to the Corporation.


EX-3.2 3 brhc10037433_ex3-2.htm EXHIBIT 3.2
Exhibit 3.2
 
AMENDED AND RESTATED BYLAWS

OF

INTERSECT ENT, INC.

ARTICLE I
 
Offices

SECTION 1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of the Corporation Service Company, 241 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, and said corporation shall be the registered agent of this corporation in charge thereof.
 
SECTION 2. OTHER OFFICES. The corporation may have other offices, either within or without the State of Delaware, at such place or places as the Board of Directors may from time to time appoint or the business of the corporation may require.

ARTICLE II

MEETING OF STOCKHOLDERS
 
SECTION 1. ANNUAL MEETINGS. Annual meetings of stockholders for the election of directors and for such other business as may be stated in the notice of the meeting, shall be held at such place, either within or without the State of Delaware, and at such time and date as the Board of Directors, by resolution, shall determine and as set forth in the notice of the meeting.
 
If the date of the annual meeting shall fall upon a legal holiday, the meeting shall be held on the next business day. At each annual meeting, the stockholders entitled to vote shall elect a Board of Directors and they may transact such other corporate business as shall be stated in the notice of the meeting.
 
SECTION 2. OTHER MEETINGS. Meetings of stockholders for any purpose other than the election of directors may be held at such time and place, within or without the State of Delaware, as shall be stated in the notice of meeting.
 
SECTION 3. VOTING. Each stockholder entitled to vote in accordance with the terms of the Certificate of Incorporation and in accordance with the provisions of these Bylaws shall be entitled to one vote, in person or by proxy, for each share of stock entitled to vote held by such stockholder, but no proxy shall be voted after three years from its date unless such proxy provides for a longer period. Upon the demand of any stockholder, the vote for directors and the vote upon any question before the meeting, shall be by ballot. All elections for directors shall be decided by plurality vote; all questions shall be decided by majority vote except as otherwise provided by the Certificate of Incorporation or the laws of the State of Delaware.

A complete list of the stockholders entitled to vote at the ensuing election, arranged in alphabetical order, with the address of each, and the number of shares held by each, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held. The list shall also be produced and kept at the meeting and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present.
 
SECTION 4. QUORUM. Except as otherwise required by law, by the Certificate of Incorporation or by these Bylaws, the presence, in person or by proxy, of stockholders holding a majority of the stock of the corporation entitled to vote shall constitute a quorum at all meetings of the stockholders.  In case a quorum shall not be present at any meeting, a majority in interest of the stockholders entitled to vote thereat, present in person or by proxy, shall have the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until the requisite amount of stock entitled to vote shall be present. At any such adjourned meeting at which the requisite amount of stock entitled to vote shall be represented, any business may be transacted which might have been transacted at the meeting as originally noticed; but only those stockholders entitled to vote at the meeting as originally noticed shall be entitled to vote at any adjournment or adjournments thereof.
 
SECTION 5. SPECIAL MEETINGS. Special meetings of the stockholders for any purpose or purposes may be called by the President or Secretary, or by resolution of the directors.

SECTION 6. NOTICE OF MEETINGS. Written notice, stating the place, date and time of the meeting, and the general nature of the business to be considered, shall be given to each stockholder entitled to vote thereat at his address as it appears on the records of the corporation, not less than ten nor more than sixty days before the date of the meeting. No business other than that stated in the notice shall be transacted at any meeting without the unanimous consent of all the stockholders entitled to vote thereat.
 
SECTION 7. ACTION WITHOUT MEETING. Unless otherwise provided by the Certificate of Incorporation, any action required to be taken at any annual or special meeting of stockholders, or any action which may be taken at any annual or special meeting, may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

ARTICLE III

DIRECTORS
 
SECTION 1. NUMBER AND TERM. The Board of Directors shall consist of one or more members. At each annual meeting, the stockholders shall determine the number of directors; provided, that between annual meetings the authorized number of directors may be increased or decreased by the stockholders. A director shall hold office until a successor is elected and qualified, or until the earlier death, resignation, disqualification, or removal of the director.
 
SECTION 2. RESIGNATIONS. Any director, member of a committee or other officer may resign at any time. Such resignation shall be made in writing, and shall take effect at the time specified therein, and if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective.
 
SECTION 3. VACANCIES. If the office of any director, member of a committee or other officer becomes vacant, the remaining directors in office, though less than a quorum, by a majority vote, may appoint any qualified person to fill such vacancy, who shall hold office for the unexpired term and until his successor shall be duly chosen.
 
SECTION 4. REMOVAL. Except as hereinafter provided, any director or directors may be removed either for or without cause at any time by the affirmative vote of the holders of a majority of all the shares of stock outstanding and entitled to vote, at a special meeting of the stockholders called for the purpose and the vacancies thus created may be filled, at the meeting held for the purpose of removal, by the affirmative vote of a majority in interest of the stockholders entitled to vote.
 
Unless the Certificate of Incorporation otherwise provides, stockholders may effect removal of a director who is a member of a classified Board of Directors only for cause. If the Certificate of Incorporation provides for cumulative voting and if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or if there be classes of directors, at an election of the class of directors of which he is a part.
 
If the holders of any class or series are entitled to elect one or more directors by the provisions of the Certificate of Incorporation, these provisions shall apply, in respect to the removal without cause of a director or directors so elected, to the vote of the holders of the outstanding shares of that class or series and not to the vote of the outstanding shares as a whole.
 
SECTION 5. INCREASE OF NUMBER. The number of directors may be increased by amendment of these Bylaws by the affirmative vote of a majority of the directors, though less than a quorum, or, by the affirmative vote of a majority interest of the stockholders, at the annual meeting or at a special meeting called for that purpose, and by like vote the additional directors may be chosen at such meeting to hold office until the next annual election and until their successors are elected and qualify.

SECTION 6. POWERS.  The Board of Directors shall exercise all of the powers of the corporation except such as are by law, or by the Certificate of Incorporation of the corporation or by these Bylaws, conferred upon or reserved to the stockholders.
 
SECTION 7. COMMITTEES. The Board of Directors may, by resolution or resolutions passed by a majority of the whole Board of Directors, designate one or more committees, each committee to consist of two or more directors of the corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.
 
Any such committee, to the extent provided in the resolution of the Board of Directors, or in these Bylaws, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Certificate of Incorporation, adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the corporation’s property and assets, recommending to the stockholders a dissolution of the corporation or a revocation of a dissolution, or amending the Bylaws of the corporation; and, unless the resolution, these Bylaws, or the Certificate of Incorporation expressly so provide, no such committee shall have the power or authority to declare a dividend or to authorize the issuance of stock.
 
SECTION 8. MEETINGS. Regular meetings of the directors may be held without notice at such places and times as shall be determined from time to time by resolution of the directors.
 
Special meetings of the board may be called by the President or by the Secretary on the written request of any two directors on at least two day’s notice to each director and shall be held at such place or places as may be determined by the directors, or shall be stated in the call of the meeting.
 
Unless otherwise restricted by the Certificate of Incorporation or by these Bylaws, members of the Board of Directors, or any committee designated by the Board of Directors, may participate in a meeting of the Board of Directors, or any committee, by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting.

SECTION 9. QUORUM. A majority of the directors shall constitute a quorum for the transaction of business. If at any meeting of the board there shall be less than a quorum present, a majority of those present may adjourn the meeting from time to time until a quorum is obtained, and no further notice thereof need be given other than by announcement at the meeting which shall be so adjourned.

SECTION 10. COMPENSATION. Directors shall not receive any stated salary for their services as directors or as members of committees, but by resolution of the board a fixed fee and expenses of attendance may be allowed for attendance at each meeting. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.

SECTION 11. ACTION WITHOUT MEETING. Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting, if prior to such action a written consent thereto is signed by all members of the board, or of such committee as the case may be, and such written consent is filed with the minutes of proceedings of the board or committee.

ARTICLE IV

OFFICERS
 
SECTION 1. OFFICERS. The officers of the corporation shall be a President, a Secretary, and a Treasurer, all of whom shall be elected by the Board of Directors and who shall hold office until their successors are elected and qualified. In addition, the Board of Directors may elect a Chairman, one or more Vice-Presidents and such Assistant Secretaries and Assistant Treasurers as they may deem proper. None of the officers of the corporation need be directors. The officers shall be elected at the first meeting of the Board of Directors after each annual meeting. Two or more offices may be held by the same person.
 
SECTION 2. OTHER OFFICERS AND AGENTS.  The Board of Directors may appoint such other officers and agents as it may deem advisable, who shall hold their offices for such terms and shall exercise such powers and perform such duties as shall be determined from time to time by the Board of Directors.
 
SECTION 3. CHAIRMAN. The Chairman of the Board of Directors, if one be elected, shall preside at all meetings of the Board of Directors and he shall have and perform such other duties as from time to time may be assigned to him by the Board of Directors.
 
SECTION 4.  PRESIDENT.  The President shall be the chief executive officer of the corporation and shall have the general powers and duties of supervision and management usually vested in the office of President of a corporation. He shall preside at all meetings of the stockholders if present thereat, and in the absence or nonelection of the Chairman of the Board of Directors, at all meetings of the Board of Directors, and shall have general supervision, direction and control of the business of the corporation. Except as the Board of Directors shall authorize the execution thereof in some other manner, he shall execute bonds, mortgages and other contracts in behalf of the corporation, and shall cause the seal to be affixed to any instrument requiring it and when so affixed the seal shall be attested by the signature of the Secretary or the Treasurer or an Assistant Secretary or an Assistant Treasurer.

SECTION 5. VICE-PRESIDENT. Each Vice-President shall have such powers and shall perform such duties as shall be assigned to him by the directors.

SECTION 6. SECRETARY. The Secretary shall give, or cause to be given, notice of all meetings of stockholders and directors, and all other notices required by law or by these Bylaws, and in case of his absence or refusal or neglect so to do, any such notice may be given by any person thereunto directed by the President, or by the directors, or stockholders, upon whose requisition the meeting is called as provided in these Bylaws. He shall record all the proceedings of the meetings of the corporation and of the directors in a book to be kept for that purpose, and shall perform such other duties as may be assigned to him by the directors or the President. He shall have the custody of the seal of the corporation and shall affix the same to all instruments requiring it, when authorized by the directors or the President, and attest the same.
 
SECTION 7. TREASURER. The Treasurer shall have the custody of the corporate funds and securities and shall keep full and accurate account of receipts and disbursements in books belonging to the corporation. He shall deposit all moneys and other valuables in the name and to the credit of the corporation in such depositaries as may be designated by the Board of Directors.
 
The Treasurer shall disburse the funds of the corporation as may be ordered by the Board of Directors, or the President, taking proper vouchers for such disbursements. He shall render to the President and Board of Directors at the regular meetings of the Board of Directors, or whenever they may request it, an account of all his transactions as Treasurer and of the financial condition of the corporation. If required by the Board of Directors, he shall give the corporation a bond for the faithful discharge of his duties in such amount and with such surety as the board shall prescribe.
 
SECTION 8. ASSISTANT TREASURERS AND ASSISTANT SECRETARIES. Assistant Treasurers and Assistant Secretaries, if any, shall be elected and shall have such powers and shall perform such duties as shall be assigned to them, respectively, by the directors.

ARTICLE V

MISCELLANEOUS
 
SECTION 1. CERTIFICATES OF STOCK. Certificate of stock, signed by the, President, Vice-President, Treasurer, Assistant Treasurer, Secretary or Assistant Secretary, may be issued or remain uncertificated. Any of or all the signatures may be facsimiles. The Corporation shall maintain a stock register in the form attached as Exhibit A.
 
SECTION 2. LOST CERTIFICATES. A new certificate of stock may be issued in the place of any certificate theretofore issued by the corporation, alleged to have been lost or destroyed, and the directors may, in their discretion, require the owner of the lost or destroyed certificate, or his legal representatives, to give the corporation a bond, in such sum as they may direct, not exceeding double the value of the stock, to indemnify the corporation against any claim that may be made against it on account of the alleged loss of any such certificate, or the issuance of any such new certificate.

SECTION 3. TRANSFER OF SHARES. The shares of stock of the corporation shall be transferable only upon its books by the holders thereof in person or by their duly authorized attorneys or legal representatives, and upon such transfer the old certificates shall be surrendered to the corporation by the delivery thereof to the person in charge of the stock and transfer books and ledgers, or to such other person as the directors may designate, by whom they shall be cancelled, and new certificates shall thereupon be issued.  A record shall be made of each transfer and whenever a transfer shall be made for collateral security, and not absolutely, it shall be so expressed in the entry of the transfer.
 
SECTION 4. STOCKHOLDERS RECORD DATE. In order that the
corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which shall not be more than sixty nor less than ten days before the date of such meeting, nor more than sixty days prior to any other action. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
 
SECTION 5. DIVIDENDS. Subject to the provisions of the Certificate of Incorporation, the Board of Directors may, out of funds legally available therefor at any regular or special meeting, declare dividends upon the capital stock of the corporation as and when they deem expedient. Before declaring any dividend there may be set apart out of any funds of the corporation available for dividends, such sum or sums as the directors from time to time in their discretion deem proper for working capital or as a reserve fund to meet contingencies or for equalizing dividends or for such other purposes as the directors shall deem conducive to the interests of the company.
 
SECTION 6. NO CORPORATE SEAL. There shall be no corporate seal.
 
SECTION 7. FISCAL YEAR. The fiscal year of the corporation shall be the 52 or 53-week period ending on the last Friday in April of each year.
 
SECTION 8. CHECKS. All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the corporation shall be signed by such officer or officers, agent or agents of the corporation, and in such manner as shall be determined from time to time by resolutions of the Board of Directors.
 
SECTION 9. NOTICE AND WAIVER OF NOTICE. Whenever any notice is required by these Bylaws to be given, personal notice is not meant unless expressly so stated, and any notice so required shall be deemed to be sufficient if given by depositing the same in the United States mail, postage prepaid, addressed to the person entitled thereto at his address as it appears on the records of the corporation, and such notice shall be deemed to have been given on the day of such mailing.  Stockholders not entitled to vote shall not be entitled to receive notice of any meetings except as otherwise provided by Statute.

Whenever any notice whatever is required to be given under the provisions of any law, or under the provisions of the Certificate of Incorporation of the corporation or these Bylaws, a waiver thereof in writing, signed by the person or persons entitled to said notice, whether before or after the time stated therein, shall be deemed equivalent thereto.

ARTICLE VI

INDEMNIFICATION AND INSURANCE

SECTION 1. NATURE OF INDEMNITY. The corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was or has agreed to become a director or officer of the corporation, or is or was serving or has agreed to serve at the request of the corporation as director or officer, of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, and may indemnify any person who was or is a party or is threatened to be made a party to such an action, suit or proceeding by reason of the fact that he is or was or has agreed to become an employee or agent of the corporation, or is or was serving or has agreed to serve at the request of the corporation as an employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with such action, suit or proceeding and any appeal therefrom, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful; except that in the case of an action or suit by or in the right of the corporation to procure a judgment in its favor (1) such indemnification shall be limited to expenses (including attorneys’ fees) actually and reasonably incurred by such person in the defense or settlement of such action or suit, and (2) no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful.
 
SECTION 2. SUCCESSFUL DEFENSE. To the extent that a director, officer, employee or agent of the corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 1 hereof or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by him in connection therewith.

SECTION 3. DETERMINATION THAT INDEMNIFICATION IS PROPER. Any indemnification of a director or officer of the corporation under Section 1 hereof (unless ordered by a court) shall be made by the corporation unless a determination is made that indemnification of the director or officer is not proper in the circumstances because he has not met the applicable standard of conduct set forth in Section 1 hereof. Any indemnification of an employee or agent of the corporation under Section 1 hereof (unless ordered by a court) may be made by the corporation upon a determination that indemnification of the employee or agent is proper in the circumstances because he has met the applicable standard of conduct set forth in Section 1 hereof. Any such determination shall be made (1) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit or proceeding, or (2) if such a quorum is not obtainable, or, even if obtainable a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, or (3) by the stockholders.
 
SECTION 4. ADVANCE PAYMENT OF EXPENSES. Expenses incurred by a director or officer in defending a civil or criminal action, suit or proceeding shall be paid by the corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by the corporation as authorized in this Article. Such expenses incurred by other employees and agents may be so paid upon such terms and conditions, if any, as the Board of Directors deems appropriate.
 
SECTION 5. PROCEDURE FOR INDEMNIFICATION OF DIRECTORS AND OFFICERS. Any indemnification of a director or officer of the corporation under Sections 1 and 2 or advance of costs, charges and expenses to a director or officer under Section 4 of this Article, shall be made promptly, and in any event within thirty days, upon the written request of the director or officer. If a determination by the corporation that the director or officer is entitled to indemnification pursuant to this Article is required, and the corporation fails to respond within sixty days to a written request for indemnity, the corporation shall be deemed to have approved such request. If the corporation denies a written request for indemnity or advancement of expenses, in whole or in part, or if payment in full pursuant to such request is not made within thirty days, the right to indemnification or advances as granted by this Article shall be enforceable by the director or officer in any court of competent jurisdiction. Such person’s costs and expenses incurred in connection with successfully establishing his right to indemnification, in whole or in part, in any such action shall also be indemnified by the corporation. It shall be a defense to any such action (other than an action brought to enforce a claim for the advance of costs, charges and expenses under Section 4 of this Article where the required undertaking, if any, has been received by the corporation) that the claimant has not met the standard of conduct set forth in Section 1 of this Article, but the burden of proving such defense shall be on the corporation. Neither the failure of the corporation (including its Board of Directors, its independent legal counsel, and its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in Section 1 of this Article, nor the conduct set forth in Section 1 of this Article, nor the fact that there has been an actual determination by the corporation (including its Board of Directors, its independent legal counsel, and its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

SECTION 6. SURVIVAL; PRESERVATION OF OTHER RIGHTS. The foregoing indemnification provisions shall be deemed to be a contract between the corporation and each director, officer, employee and agent who serves in any such capacity at any time while these provisions as well as the relevant provisions of the Delaware General Corporation Law are not in effect and any repeal or modification thereof shall not affect any right or obligation then existing with respect to any state of facts then or previously existing or any action, suit, or proceeding previously or thereafter brought or threatened based in whole or in part upon any such state of facts.  Such a “contract right” may not be modified retroactively without the consent of such director, officer, employee or agent.
 
The indemnification provided by this Article shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any other Bylaw, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in any other capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors and administrators of such a person. The corporation may enter into a separate written agreement with any director, officer, employee or agent of the corporation that expressly provides for indemnification and reimbursement of such person to the full extent permitted by this Article, on the same terms and conditions provided herein.
 
SECTION 7. INSURANCE. The corporation may purchase and maintain insurance on behalf of any person who is or was or has agreed to become a director or officer of the corporation, or is or was serving at the request of the corporation as director or officer of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him or on his behalf in any such capacity, or arising out of his status as such, whether or not the corporation should have the power to indemnify him against such liability under the provisions of this Article.
 
SECTION 8. SEVERABILITY. If this Article or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director or officer and may indemnify each employee or agent of the corporation as to costs, charges and expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement with respect to any action, suit or proceeding, whether civil, criminal, administrative or investigative, including an action by or in the right of the corporation, to the fullest extent permitted by any applicable portion of this Article that shall not have been invalidated and to the fullest extent permitted by applicable law.

ARTICLE VII

AMENDMENTS

These Bylaws may be altered or repealed and Bylaws may be made at any annual meeting of the stockholders or at any special meeting thereof if notice of the proposed alteration or repeal or Bylaw or Bylaws to be made be contained in the notice of such special meeting, by the affirmative vote of a majority of the stock issued and outstanding and entitled to vote thereat, or by the affirmative vote of a majority of the Board of Directors, at any regular meeting of the Board of Directors, or at any special meeting of the Board of Directors, if notice of the proposed alteration or repeal, or Bylaw or Bylaws to be made, be contained in the notice of such special meeting.

Exhibit A
 
STOCK REGISTER

Intersect ENT, Inc.
Par value $0.01
Total Authorized: 1,000 Common Shares
       
NAME
# OF SHARES
ISSUED
DATED
NOTES
Medtronic, Inc.
100
July 28, 2021
  
       
       
       
       
       
       
       


EX-99.1 4 brhc10037433_99-1.htm EXHIBIT 99.1
Exhibit 99.1

NEWS RELEASE

  Contacts:    
       
 
 Brett Cromwell
 
 Ryan Weispfenning
 
 Public Relations
 
 Investor Relations
 
 +1-617-899-7091 
 
 +1-763-505-4626


FOR IMMEDIATE RELEASE

Medtronic completes acquisition of Intersect ENT

Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio

DUBLIN and MENLO PARK, Calif. – May 13, 2022 – Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT, expanding the company’s comprehensive ear, nose, and throat (ENT) portfolio with innovative products used in sinus procedures to improve post-operative outcomes and to treat nasal polyps.

As a result of the close of the transaction announced on Aug. 6, 2021, Medtronic has acquired Intersect ENT’s PROPEL™ and SINUVA™ (mometasone furoate) sinus implant product lines and technology, intellectual property, and Menlo Park, Calif., facility. Intersect ENT employees also join Medtronic through this acquisition. A former Intersect ENT brand, Fiagon, was divested simultaneously at close, and those products ― Cube™ navigation system and VenSure™ balloon sinus dilation system ― were not included in the acquisition.

Intersect ENT’s product lines and customer base will further the efforts of Medtronic to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). CRS is one of the most common health care problems in the U.S., with approximately 30 million adults diagnosed annually. It has been associated with lost days of work, decreased productivity, and even depression and anxiety, with most patients reporting 5-15+ years of suffering and medical treatment.

Through this acquisition, Medtronic gains PROPEL and SINUVA, which are unique bioabsorbable, steroid-eluting implants for sinus patients. PROPEL implants are inserted following endoscopic sinus surgery to maintain sinus patency and provide localized steroid delivery. SINUVA implants are designed for use in the physician’s office setting for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery.

“By combining Intersect ENT’s groundbreaking localized drug delivery products with the leading navigation and powered instruments of Medtronic, we can now equip physicians with the right tools for many unique patient needs,” said Vince Racano, president of the ENT business, which is part of the Neuroscience Portfolio at Medtronic. “This acquisition expands our portfolio, and we can now provide a more comprehensive continuum of care for CRS patients while supporting the bold ambition of Medtronic to be the global healthcare technology leader.”

“We believe the market leadership and global footprint of Medtronic, coupled with enterprise resources to fuel pipeline innovation and commercialization, will advance our reach to customers and patients more quickly and serve our shared vision of improving patient access, outcomes, and satisfaction for millions of people around the world who suffer from ENT diseases,” said Thomas West, president and CEO of Intersect ENT. “We are thrilled to combine these two companies as we now officially work together to bring more ENT options to patients. I am especially proud of our dedicated Intersect ENT employees, whose entrepreneurial spirit and passion for innovation have driven our ability to achieve this milestone.”

PROPEL™, PROPEL™ Mini, and PROPEL™ Contour implants are FDA approved in the U.S. and CE marked in the EU. SINUVA™ Sinus Implants are currently sold only in the U.S.

This acquisition is consistent with the strong commitment of Medtronic to strategic portfolio management and capital deployment — disciplined processes to accelerate the company’s weighted average market growth rate by strategically allocating resources to fuel innovation in fast-growing markets.

The Medtronic financial advisor for the transaction is Perella Weinberg Partners LP, with Ropes & Gray LLP acting as legal advisor. Intersect ENT’s financial advisor is Goldman Sachs & Co. LLC, with Cooley LLP acting as legal advisor.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (the “Act”), including statements containing the words “expect,” “intend,” “plan,” “believe,” “will,” “should,” “would,” “could,” “may,” and words of similar meaning, as well as other words or expressions referencing future events, conditions or circumstances. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Act. Statements that describe or relate to Medtronic’s plans, goals, intentions, strategies, or financial outlook, including the expected accretive impact of the acquisition, and statements that do not relate to historical or current fact, are examples of forward-looking statements. Examples of forward-looking statements include, without limitation, statements regarding Medtronic’s expected strategy to drive revenue and share growth and the ability of Medtronic to implement its plans, forecasts and other expectations with respect to its business after the completion of the transaction and realize expected benefits. Forward-looking statements are not guarantees of future performance, and there are a number of important factors that could cause actual outcomes and results to differ materially from the results contemplated by such forward-looking statements, including those factors listed in Item 1A “Risk Factors” of Medtronic’s Annual Report on Form 10-K filed with the SEC on June 25, 2021 and those factors detailed from time to time in Medtronic’s other SEC reports including quarterly reports on Form 10-Q and current reports on Form 8-K. Medtronic does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.
-end-

INDICATION
SINUVA Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
Patients with a known hypersensitivity to mometasone furoate or any of the ingredients in SINUVA should not use SINUVA.

WARNINGS AND PRECAUTIONS
Local Effects: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

Ocular Effects: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

Immunosuppression: Patients taking corticosteroids are more susceptible to a more serious or even fatal course of chickenpox or measles than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

ADVERSE REACTIONS
The most common adverse reactions observed (> 1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

Rx only. Please see Full Prescribing Information for SINUVA at sinuva.com/hcp.

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

 EX-101.SCH 5 xent-20220513.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 xent-20220513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 7 xent-20220513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 8 image0.jpg begin 644 image0.jpg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htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 13, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 13, 2022
Current Fiscal Year End Date --12-31
Entity Registrant Name Intersect ENT, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36545
Entity Tax Identification Number 20-0280837
Entity Address, Address Line One 1555 Adams Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 650
Local Phone Number 641-2100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001271214
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol XENT
Security Exchange Name NASDAQ
XML 10 brhc10037433_8k_htm.xml IDEA: XBRL DOCUMENT 0001271214 2022-05-13 2022-05-13 false --12-31 0001271214 8-K 2022-05-13 Intersect ENT, Inc. DE 001-36545 20-0280837 1555 Adams Drive Menlo Park CA 94025 650 641-2100 false false false false Common Stock, $0.001 par value XENT NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://intersectent.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10037433_8k.htm brhc10037433_99-1.htm brhc10037433_ex3-1.htm brhc10037433_ex3-2.htm xent-20220513.xsd xent-20220513_lab.xml xent-20220513_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10037433_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "brhc10037433_8k.htm" ] }, "labelLink": { "local": [ "xent-20220513_lab.xml" ] }, "presentationLink": { "local": [ "xent-20220513_pre.xml" ] }, "schema": { "local": [ "xent-20220513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 30, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "xent", "nsuri": "http://intersectent.com/20220513", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037433_8k.htm", "contextRef": "c20220513to20220513", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://intersectent.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037433_8k.htm", "contextRef": "c20220513to20220513", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intersectent.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001140361-22-018976-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-018976-xbrl.zip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end